|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The glioblastoma multiforme treatment market is poised to grow at a CAGR of 8% during the forecast period (2022-2027).
Regardless of the COVID-19 infection, the treatment of neuro-oncological patients cannot be significantly delayed. As a result, during the pandemic, doctors faced numerous challenges in finding the right balance between treating the SARS-CoV-2 infection and treating the patient's neuro-oncological status. According to the study titled "Glioblastoma Multiforme in The COVID-19 Era: How Italy Managed to Surgically Treat the Neuro-Oncological Patient Despite the Pandemic" published in the Annals of Clinical Medicine in January 2021, surgical operations for patients with glioblastoma were not always possible during the pandemic; in fact, neurosurgeons at Mount Sinai Hospital in New York decided to postpone the surgeries, opting instead for radiotherapy and high doses of steroids. The result was a decrease in patients' overall survival as well as a worsening of their neuro-oncological clinical status. Moreover, according to the study titled "Impact of COVID-19 Pandemic on the Management of Glioma Patients Around the World. An Evidence-Based Review" published in Brain Disorder in June 2021, the number of surgical admissions for glioma patients did not differ significantly between COVID-19 negative and COVID-19 positive cases. However, researchers discovered that both overall complications and mortality outcomes were more significant in COVID-19 negative patients from the reported studies. Thus, such incidents are anticipated to impact the growth of the market over the pandemic phase.
Furthermore, factors such as the increasing burden of brain disorders, strong R&D initiatives from key players, and a rising geriatric population are boosting the growth of the glioblastoma multiforme treatment market.
According to the American Association of Neurological Surgeons, in June 2021, glioblastoma is the most common type of malignant brain and CNS tumor, accounting for 47.7% of all cases. The incidence of glioblastoma is 3.21 per 100,000 people. The median age of diagnosis is 64 years, and men are more likely than women to be diagnosed. The survival rate in the first year after diagnosis is approximately 40% and 17% in the second year. Furthermore, according to the World Health Organization (WHO) May 2021, globally, an estimated 245,000 cases of brain and nervous system tumors are reported each year. According to the Global Cancer Observatory, the global incidence of brain and CNS cancers was 308,102 in 2020, with 251,329 deaths. This leads to increased care providers shifting to the mainstream treatment associated with glioblastoma treatment. As a result, the growing emphasis on developing better treatment options is providing lucrative opportunities for cancer chemotherapy-based companies to generate innovative drugs as well as explore different geographic regions to expand their geographical reach, ultimately fueling the growth of the glioblastoma multiforme treatment market.
Moreover, various initiatives undertaken by the regional and state governments to make the treatment more accessible to patients are anticipated to boost the market growth further. In December 2021, the Patient Access Network (PAN) Foundation and the American Brain Tumor Association introduced a new collaboration to assist people living with glioblastoma, providing up to USD 1,600 per year in financial assistance and support services for patients and their caregivers. Additionally, product launches and approvals by the key market players are expected to bolster the market's growth over the forecast period. For instance, in December 2020, CNS Pharmaceuticals, Inc. reported that the Food and Drug Administration approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme. Moreover, in August 2021, the Food and Drug Administration granted orphan drug designation to LP-184 (Lantern Pharma) for the treatment of glioblastoma multiforme and other malignant gliomas. Also, in May 2020, Lantern Pharma Inc. held a webinar that concentrated on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM and other types of brain cancer.
However, reimbursement issues, stringent regulatory guidelines, and high cost & side effects associated with therapies are expected to restrain the growth of the global market over the analysis period.
Scope of the Report
As per the scope of the report, glioblastoma multiforme (GBM), also known as glioblastoma, is the most common type of malignant brain tumor. A brain tumor arises from the abnormal growth of cancerous cells in the brain. The Glioblastoma Multiforme Treatment Market is Segmented by Treatment (Chemotherapy, Radiation Therapy, and Other Treatments), End-User (Hospitals/Clinics and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for the above segments.
|By End User|
|Ambulatory Surgical Centers|
Key Market Trends
Chemotherapy Segment is Expected to Dominate the Market Over the Forecast Period
The chemotherapy segment is expected to dominate the market. The key factors contributing to the growth of the segment are the rising number of brain and other nervous system cancers and the growing preference and commercial availability of chemotherapeutic agents for treating glioblastoma.
As per the study titled "Glioblastoma Multiforme" published in the National Library of Medicine in November 2021, Glioblastoma multiforme (GBM) has a low overall survival rate and a high rate of recurrence, owing to its aggressive character. After surgical resection, radiation and chemotherapy are the mainstays of treatment. Furthermore, according to a study titled "Current Immunotherapies for Glioblastoma Multiforme" published in Frontiers of Immunology in March 2021, in clinical studies against GBM, combinatorial therapy of PD-1/PD-L1 antibodies with radiation therapy and/or chemotherapy appears to be more promising than monotherapy with PD-1/PD-L1 inhibitors, which has had limited effectiveness.
Likewise, many companies are focusing on developing and approving newer drugs for neurological diseases like brain stroke as well as glioblastoma to maintain their competitive edge and penetrate new regional markets across the developed and emerging regions. For instance, in July 2020, the United States Food and Drug Administration granted Denovo Biopharma's DB102 (enzastaurin) fast-track designation for the treatment of patients newly diagnosed with glioblastoma. In addition, the pipeline of glioblastoma multiforme is strong with the number of drugs that are expected to receive FDA approval steadily over the coming years.
Additionally, a study titled "Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments" published on PubMed.gov in April 2020 stated that for patients with glioblastoma, three chemotherapeutic drugs (temozolomide, bevacizumab, and carmustine) are currently available. The addition of temozolomide to radiation considerably increases overall survival, according to the findings of a randomized clinical trial including 573 patients (27.2% vs. 10.9% in the radiotherapy alone at 2 years). According to the same study, the methylation of the O6-methylguanine-DNA-methyltransferase (MGMT) gene was a strong predictive indicator for temozolomide chemotherapy in newly diagnosed patients.
Thus, all the aforementioned factors are anticipated to boost the segment over the forecast period.
To understand key trends, Download Sample Report
North America leads the Glioblastoma Multiforme Treatment Market Over the Forecast Period
North America leads the glioblastoma multiforme treatment market, owing to a rise in funding initiatives and awareness among the patient population. Government support for the development of the healthcare sector, widespread awareness of brain disorders and tumors, easy access to high-quality medical facilities, and favorable reimbursement policies are among the key factors driving the regional market's growth. According to the American Society of Clinical Oncology (ASCO), in February 2022, it was expected that an estimated 25,050 adults (14,170 men and 10,880 women) in the United States would be diagnosed with primary cancerous tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary CNS tumors. Moreover, about 4,170 children under the age of 15 were diagnosed with a brain or CNS tumor this year in the United States.
Furthermore, strategic activities by the key market players in the region are anticipated to boost the market's growth. For instance, in July 2021, QV Bioelectronics, a medical device start-up developing a first-of-its-kind electric field therapy implant for glioblastoma multiforme, announced significant funding support through a recently completed seed investment round to advance the development of its innovative GRACE implant. The GRACE implant will deliver electric therapy in the hopes of preventing cancer cell division and slowing tumor growth.
Additionally, mergers and acquisitions, as well as licensing and partnerships, are being pursued by major players to strengthen their product portfolios, expand their manufacturing capacities, and provide competitive differentiation. For instance, in April 2021, Lineage Cell Therapeutics signed a licensing agreement with Immunomic Therapeutics for the development of an allogeneic VAC cancer immunotherapy platform to treat glioblastoma multiforme. Under the terms of the agreement, Lineage will receive a USD 2 million upfront payment, followed by USD 67 million in commercial milestone payments.
Thus, given the aforementioned factors, the glioblastoma multiforme treatment market is expected to grow significantly over the forecast period in North America.
To understand geography trends, Download Sample Report
The leading players in the global glioblastoma multiforme treatment market are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.
Arbor Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd
Merck & Co. Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
- In August 2022, Northwest Biotherapeutics received approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for the Company's Pediatric Investigation Plan (PIP). The development, regulatory review, and regulatory approval of a PIP is a prerequisite for the application for approval of new medicine for adult patients, such as DCVax-L.
- In July 2022, Diffusion Pharmaceuticals initiated a Phase II trial in patients with glioblastoma multiforme incorporating innovative imaging methodology to evaluate tumor oxygenation.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Brain Disorders
4.2.2 Strong R&D Initiatives from Key Players
4.2.3 Increasing Aging Population
4.3 Market Restraints
4.3.1 Reimbursement Issues and Stringent Regulatory Guidelines
4.3.2 High Cost and Side Effects Associated with Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment
220.127.116.11 Other Types of Chemotherapy
5.1.2 Radiation Therapy
5.1.3 Other Treatments
5.2 By End User
5.2.2 Ambulatory Surgical Centers
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Arbor Pharmaceuticals, LLC
6.1.2 Bristol-Myers Squibb Company
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Merck & Co. Inc.
6.1.6 Sun Pharmaceutical Industries Ltd.
6.1.7 Lanthen Pharmaceutical
6.1.8 Pfizer Inc.
6.1.9 Amgen Inc.
6.1.10 Teva Pharmaceutical Industries Ltd.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Glioblastoma Multiforme Treatment Market market is studied from 2019 - 2027.
What is the growth rate of Glioblastoma Multiforme Treatment Market?
The Glioblastoma Multiforme Treatment Market is growing at a CAGR of 8% over the next 5 years.
Which region has highest growth rate in Glioblastoma Multiforme Treatment Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Glioblastoma Multiforme Treatment Market?
North America holds highest share in 2021.
Who are the key players in Glioblastoma Multiforme Treatment Market?
Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. are the major companies operating in Glioblastoma Multiforme Treatment Market.